| Targeting chelatable iron as a therapeutic modality in Parkinson's disease D Devos, C Moreau, JC Devedjian, J Kluza, M Petrault, C Laloux, ... Antioxidants & redox signaling 21 (2), 195-210, 2014 | 624 | 2014 |
| Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1 N Sergeant, B Sablonnière, S Schraen-Maschke, A Ghestem, ... Human molecular genetics 10 (19), 2143-2155, 2001 | 333 | 2001 |
| Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study DJH Moss, AF Pardiñas, D Langbehn, K Lo, BR Leavitt, R Roos, A Durr, ... The Lancet Neurology 16 (9), 701-711, 2017 | 320 | 2017 |
| Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy Y Gérard, L Maulin, Y Yazdanpanah, X De La Tribonnière, C Amiel, ... Aids 14 (17), 2723-2730, 2000 | 255 | 2000 |
| Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo … C Moreau, A Delval, L Defebvre, K Dujardin, A Duhamel, G Petyt, ... The lancet neurology 11 (7), 589-596, 2012 | 220 | 2012 |
| Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study J Dumurgier, S Schraen, A Gabelle, O Vercruysse, S Bombois, ... Alzheimer's research & therapy 7, 1-9, 2015 | 159 | 2015 |
| Tau as a biomarker of neurodegenerative diseases S Schraen-Maschke, N Sergeant, CM Dhaenens, S Bombois, ... Future Medicine Ltd 2 (4), 363-384, 2008 | 130 | 2008 |
| Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease P Nazé, I Vuillaume, A Destée, F Pasquier, B Sablonnière Neuroscience letters 328 (1), 1-4, 2002 | 125 | 2002 |
| Clinical features and genetic analysis of a new form of spinocerebellar ataxia D Devos, S Schraen–Maschke, I Vuillaume, K Dujardin, P Naze, ... Neurology 56 (2), 234-238, 2001 | 101 | 2001 |
| Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of Muscleblind-like-1 isoforms H Tran, N Gourrier, C Lemercier-Neuillet, CM Dhaenens, A Vautrin, ... Journal of Biological Chemistry 286 (18), 16435-16446, 2011 | 96 | 2011 |
| Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease G Grolez, C Moreau, B Sablonnière, G Garçon, JC Devedjian, S Meguig, ... BMC neurology 15, 1-6, 2015 | 95 | 2015 |
| A new locus for spinocerebellar ataxia (SCA21) maps to chromosome 7p21. 3‐p15. 1 I Vuillaume, D Devos, S Schraen‐Maschke, C Dina, A Lemainque, ... Annals of Neurology: Official Journal of the American Neurological …, 2002 | 95 | 2002 |
| A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease CM Dhaenens, S Burnouf, C Simonin, E Van Brussel, A Duhamel, ... Neurobiology of disease 35 (3), 474-476, 2009 | 88 | 2009 |
| Impact of harmonization of collection tubes on Alzheimer's disease diagnosis S Lehmann, S Schraen, I Quadrio, C Paquet, S Bombois, C Delaby, ... Alzheimer's & Dementia 10, S390-S394. e2, 2014 | 85 | 2014 |
| New syndromic form of benign hereditary chorea is associated with a deletion of TITF‐1 and PAX‐9 contiguous genes D Devos, I Vuillaume, A De Becdelievre, B De Martinville, CM Dhaenens, ... Movement disorders: official journal of the Movement Disorder Society 21 (12 …, 2006 | 83 | 2006 |
| Association between caffeine intake and age at onset in Huntington's disease C Simonin, C Duru, J Salleron, P Hincker, P Charles, A Delval, K Youssov, ... Neurobiology of disease 58, 179-182, 2013 | 82 | 2013 |
| ETR‐3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I O Leroy, CM Dhaenens, S Schraen‐Maschke, K Belarbi, A Delacourte, ... Journal of neuroscience research 84 (4), 852-859, 2006 | 78 | 2006 |
| TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment J Delplanque, D Devos, V Huin, A Genet, O Sand, C Moreau, C Goizet, ... Brain 137 (10), 2657-2663, 2014 | 77 | 2014 |
| Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease D Devos, S Lejeune, F Cormier-Dequaire, K Tahiri, ... Parkinsonism & related disorders 20 (2), 170-175, 2014 | 76 | 2014 |
| Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study C Moreau, A Delval, V Tiffreau, L Defebvre, K Dujardin, A Duhamel, ... Journal of Neurology, Neurosurgery & Psychiatry 84 (5), 552-555, 2013 | 74 | 2013 |
